Intracranial Neoplasm Clinical Trial
Official title:
Evaluation of Regional Gadolinium Retention in the Brain Using QSM With Correlation to Regional DCE MRI Permeability Using GOCART Technique in Intracranial Neoplasm Patients Receiving Gadobenate Dimeglumine (MultiHance) or Gadoterate Meglumine (Dotarem)
Verified date | April 2021 |
Source | University of Southern California |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Observational |
This randomized pilot clinical trial studies quantitative susceptibility mapping (QSM) and regional dynamic contrast enhanced (DCE) magnetic resonance imaging (MRI) permeability using golden-angle cartesian randomized time-resolved (GOCART) technique in evaluating regional gadolinium retention in the brain in patients with intracranial neoplasm receiving gadobenate dimeglumine or gadoterate meglumine. MRI diagnostic techniques such as, QSM and DCE MRI, may help to gather information regarding brain changes associated with gadolinium deposits during 8 to 18 months after administration of gadobenate dimeglumine or gadoterate meglumine.
Status | Withdrawn |
Enrollment | 0 |
Est. completion date | April 4, 2021 |
Est. primary completion date | April 4, 2020 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: - Patient with suspected intracranial neoplasm scheduled for routine MRI with GBCA (gadolinium naive patients) - Willingness to comply with the study protocol Exclusion Criteria: - Contraindications for MRI or GBCA (standard of care) - Abnormal renal function with estimated glomerular filtration rate (eGFR) less than 30 mL/min/m^2 based on creatinine obtained within last 30 days - History of previous administration of GBCA |
Country | Name | City | State |
---|---|---|---|
United States | USC / Norris Comprehensive Cancer Center | Los Angeles | California |
Lead Sponsor | Collaborator |
---|---|
University of Southern California | National Cancer Institute (NCI) |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Change in QSM score | Descriptive statistics will be used to describe the magnitude of Gd deposition measured by QSM score in each of the two study groups. Histograms will be generated for QSM score at each time point as well as the change from the baseline for each group. The descriptive statistics will be used to calculate the mean, median, interquartile range, and standard deviation. Box plot and overlying histogram will be used to illustrate the distribution of change in Gd deposition between gadobenate dimeglumine and gadoterate meglumine group. Correlation between QSM score versus (vs.) kTrans and QSM score v | Baseline up to 18 months | |
Secondary | Change in T1WI signal intensity ratio | Descriptive statistics will be used to describe the magnitude of Gd deposition measured by T1WI signal intensity ratio in each of the two study groups. Histograms will be generated for T1WI signal intensity ratio score at each time point as well as the change from the baseline for each group. The descriptive statistics will be used to calculate the mean, median, interquartile range, and standard deviation. Box plot and overlying histogram will be used to illustrate the distribution of change in Gd deposition between gadobenate dimeglumine and gadoterate meglumine group. Correlation between T1W | Baseline up to 18 months | |
Secondary | kTrans and Ve signal using GOCART 3D MRI | The signal (kTrans and Ve) will be obtained in voxel level then taking average within the region of interest (ROI). ROI will be placed on the pons, bilateral globi pallidi, thalami and dentate nuclei to obtain the average signal within the ROI. Averages of all bilateral measurements will be used to calculate the final signal for kTrans and Ve. The final kTrans and Ve signal will only be used to assess the correlation with QSM and T1WI signal intensity ratios. | Up to 18 months |
Status | Clinical Trial | Phase | |
---|---|---|---|
Active, not recruiting |
NCT05732896 -
Comparison of Opioid Consumption During TCI Guided by NOL Index or Standard Care Undergoing Intracranial Tumor Surgery
|
N/A | |
Completed |
NCT04044937 -
Fluoroethyltyrosine for Evaluation of Intracranial Neoplasms
|
Phase 2 | |
Not yet recruiting |
NCT03717766 -
Application of New Technologies in the Resection of Intracranial Tumors
|
||
Completed |
NCT05145049 -
The Relationship of Anesthesia Method With Serum Lactate Level in Craniotomies
|
||
Terminated |
NCT03089749 -
Characterization of Human Autoantibody Titers After Central Nervous System Insult
|
||
Not yet recruiting |
NCT05891002 -
Accuracy of Robotically Assisted Cranial Biopsies
|
||
Recruiting |
NCT06291662 -
Evaluation of Performance Characteristics and Applicability in Oncology of Devices Customized Medical Devices Made by 3D Printing
|
N/A | |
Completed |
NCT04302857 -
Tractography Pilot Study Leipzig
|
||
Completed |
NCT04454268 -
Intracranial Hydatid Cyst
|
N/A | |
Completed |
NCT03076255 -
Head and Neck Maskless Immobilization Device in Immobilizing Patients With Head and Neck Cancer or Intracranial Tumors Undergoing Radiation Therapy
|
N/A | |
Recruiting |
NCT04278118 -
Hypofractionated Proton Therapy for Benign Intracranial Brain Tumors, the HiPPI Study
|
N/A | |
Recruiting |
NCT03714347 -
The Effect of Cerebral Oxygenation on Postoperative Recovery in Intracranial Surgery
|
N/A | |
Completed |
NCT03710278 -
The Effectiveness and Safety of Human Lumbar Puncture Assist Device (LPat)
|
||
Completed |
NCT03539731 -
[18F]DASA-23 and PET Scan in Evaluating Pyruvate Kinase M2 Expression in Patients With Intracranial Tumors or Recurrent Glioblastoma and Healthy Volunteers
|
Phase 1 | |
Recruiting |
NCT05904704 -
Oxygen-Enhanced MRI for Generating Hypoxia Maps in Patients With Intracranial Tumors
|
N/A |